46. Ward J, Brenneman G, Letson GW, Heyward WL, the Alaska H. influenzae Vaccine Study Group. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. N Encl J Med 1990; 323 :1393 - 401.
47. Watemberg N, Dagan R, Arbelli Y, et al. Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr Infect Dis 1991; 10:758 -- 61.
48. Berger R, Just M. Lack of interference between vaccines [Letter]. Pediatr Infect Dis 1983; 2:172.
49. Deforest A, Long SS, Lischner HW, et al. Simultaneous administration of measles-mumps-rubella vaccine with booster dose of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics 1998; 81:237-46.
50. Huang LM, Lee CY, Hsu CY, et al. Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine. Pediatr Infect Dis J 1990;9:461 -- 5.
51. John TJ. Selvakumar R, Balrai V, Simoes EAF. Antibody response to measles vaccine with DTPP [Letter]. Am J Dis Child 1987; 141:14.
52. Krugman RD, Witte JJ, Parkman PD, et al. Combined administration of measles, mumps, rubella and trivalent oral poliovirus vaccines. Public Health Rep 1977; 92:220-2.
53. Rothstein E, Bernstein H, Pennridge Pediatric Association, et al. Simultaneous administration of an acellular pertussis-DT vaccine (APDT) with MMR and OPV vaccines. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11 to 14, 1992.
54. Simoes EAF, Balraj V, Selvakumar R, John TJ. Antibody response of children to measles vaccine mixed with diphtheria-pertussis-tetanus or diphtheria-pertussis-tetanus-poliomyelitis vaccine. Am J Dis Child 1988; 142:309-11.
55. Parkman PD, Hopps HE, Albrecht P, Meyer HM Jr. Simultaneous administration of vaccines: recent advances in immunization. PAHO scientific publication 451. Washington, DC: Pan American Health Organization, 1983.
56. Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bull WHO 1985; 63:1151-69.
57. Edwards KM, Decker MD, Halsey NA. et al. Differences in antibody response to whole-cell pertussis vaccines. Pediatrics 1991; 88 : 1019-23.
58. Halperin SA, Bortolussi R, MacLean D, Chisholm N. Persistence of pertussis in an immunized population: results of the Nova Scotia enhanced pertussis surveillance program. J Pediatr 1989; 115:686-93.
59. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68:650 -- 60.
60. Long SS, Deforest A, Pennridge Pediatric Associates, Smith DG, Lazaro C, Wassilak SGF. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990; 85:294-302.
61. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double blind placebo-controlled trial in twins. Lancet 1986: 2:939-42.
62. Centers for Disease Control and Prevention. Adverse events following Immunization Surveillance Report No. 3, 1985 -- 86, Issued February 1989.
63. Centers for Disease Control and Prevention. New recommended schedule for' active immunization of normal infants and children. MMWR 1986; 35:577-9.
64. Black SB, Shinefield HR. Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61 O8O children. Pediatr Infect Dis J 1991; 10:97-104.
65. Peltola H, Eskola J, Kayhty, et al. Clinical efficacy of the PRP-D vs. HbOC conjugate vaccines against Haemophilus influenzae type b (Hib). In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11 to 14, 1992.
66. Booy R, Aitken SJM, Taylor S, et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3 and 4 months versus 3, 5, and 9 months of age. Lancet 1992; 339:507-10.
67. Booy R, Moxon ER, MacFarlane JA, Mayon-White RT, Slack MPE. Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region [Letter]. Lancet 1992; 340:847.
68. Rennels MB, Edwards KM, Anderson EL, et al. Effect on pertussis immune responses of administering Haemophilus influenzae type b (HIB) at the same time as acellular or whole cell DTP vaccine. Pediatr Res 1992; 31:100A. Abstract 584.
[1] Принято для опубликования 22 февраля 1994г.
Национальная программа иммунизации, Центры по борьбе с болезнями и их профилактике, г.Атланта, шт.Джорджия.
Ключевые слова: детские прививки, неблагоприятные события, иммуногенность, одновременное введение.
Адрес для перепечаток: Gail King, M.D., M.P.H., National Immunization Program, Centers for Disease Control, 1600 Clifton Rd. N.E., MS-E61, Atlanta, GA 30333.
8-09-2015, 21:40